Network identification

PURI

https://redirect.ema.europa.eu/resource/42886

Network ID

42886

Network name and Acronym

id.DRIVE (former COVIDRIVE)

Network countries

Austria
Belgium
Croatia
Czechia
Denmark
France
Germany
Iceland
Italy
Poland
Romania
Spain

Network website

ENCePP partner

Yes
Network description
id.DRIVE is a privately funded not-for-profit public-private partnership (PPP) that facilitates the conduct of infectious diseases studies on vaccines, related preventive measures, therapeutics and diagnostics in the European region. The id.DRIVE consortium is open to new partners (public health institutes, pharmaceutical companies, small-medium enterprises, academia…) and new study sites (Study Contributors).

id.DRIVE was launched in 2024 as the successor of COVIDRIVE, a PPP that was set-up during the COVID-19 pandemic to address the joint need to monitor COVID-19 vaccination programmes for public health institutes in Europe and to assess brand-specific COVID-19 vaccine effectiveness for the pharmaceutical companies as part of their regulatory obligations. COVIDRIVE leveraged an existing vaccine effectiveness platform (DRIVE) which provided yearly brand-specific influenza vaccine effectiveness estimates to EMA.

id.DRIVE expands the scope of COVIDRIVE beyond COVID-19 and will study many different infectious diseases.
Network details
Network primary therapeutic area:
Immunological products and vaccines
Infectious diseases
Network funding:
Pharmaceutical company and other private sector 

Contact

Institutions that are part of this network

P95 Clinical and Epidemiology Services
Pfizer
AstraZeneca
The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)
Johnson & Johnson
GlaxoSmithKline (GSK)
Novavax, Valneva

Studies conducted by the network